Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast Cancer
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This study is planned to include 40 patients with HER2-negative advanced breast cancer to
receive fluzoparib combined with chidamide or fluzoparib combined with camrelizumab to
observe and evaluate the efficacy and safety of fluzoparib combined with camrelizumab or
chidamide in the treatment of HRD-positive HER2-negative advanced breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital